CENTENNIAL, Colo., Aug. 6, 2015 /PRNewswire-USNewswire/ -- AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, announced positive clinical results for the use of AlloSkin to help heal diabetic foot ulcers, venous leg ulcers or surgical/traumatic wounds.

The peer-reviewed, retrospective study, “Human Skin Allograft for Patients with Diabetic Foot Ulcers, Venous Leg Ulcers, or Surgical/Traumatic Wounds: A Retrospective, Descriptive Study,” was conducted at wound clinics in the Inova Health System and published in Ostomy Wound Management. Dr. Eric Desman was the principal investigator for this study, which included 36 patients and is the first identified study of very large chronic wounds treated with human skin allografts. The mean wound size in the study was 19.4 cm².

The study was conducted among outpatients with non-healing diabetic foot ulcers, venous leg ulcers and surgical or traumatic wounds managed with AlloSkin, a meshed, partial-thickness, cryopreserved human skin allograft. The study results showed patient healing rates of 47 percent at 12 weeks and 58 percent at 20 weeks, which is favorable in comparison to the healing rates of living cell-based skin substitutes, especially considering the large wound size in the study.

“The positive results of this study demonstrate AlloSkin is an effective treatment alternative for these types of conditions,” said Dr. Peter Stevens, PhD, AlloSource Vice President of Strategy, Development and Growth. “AlloSkin is a cost-effective solution for chronic wounds and we hope this study will help clinicians consider using allograft skin to heal more patients.”

The full study published in the July 2015 issue of Ostomy Wound Management can be found here.

About AlloSource
AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. For more than 20 years, AlloSource’s products have bridged the proven science of allografts with the advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world’s largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country’s most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org or our educational website, allograftpossibilities.org.

Media Contact
Megan Duggan
AlloSource
720. 382. 2766
mduggan@allosource.org

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/positive-clinical-results-for-allosources-alloskin-announced-300125021.html

SOURCE AlloSource